<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36293090</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>20</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>13</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Comparative Analysis of Antibody Titers against the Spike Protein of SARS-CoV-2 Variants in Infected Patient Cohorts and Diverse Vaccination Regimes.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">12231</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms232012231</ELocationID><Abstract><AbstractText>The presence of neutralizing antibodies against SARS-CoV-2 correlates with protection against infection and severe COVID-19 disease courses. Understanding the dynamics of antibody development against the SARS-CoV-2 virus is important for recommendations on vaccination strategies and on control of the COVID-19 pandemic. This study investigates the dynamics and extent of &#x3b1;-Spike-Ab development by different vaccines manufactured by Johnson &amp; Johnson, AstraZeneca, Pfizer-BioNTech and Moderna. On day 1 after vaccination, we observed a temporal low-grade inflammatory response. &#x3b1;-Spike-Ab titers were reduced after six months of vaccination with mRNA vaccines and increased 14 days after booster vaccinations to a maximum that exceeded titers from mild and critical COVID-19 and Long-COVID patients. Within the group of critical COVID-19 patients, we observed a trend for lower &#x3b1;-Spike-Ab titers in the group of patients who survived COVID-19. This trend accompanied higher numbers of pro-B cells, fewer mature B cells and a higher frequency of T follicular helper cells. Finally, we present data demonstrating that past infection with mild COVID-19 does not lead to long-term increased Ab titers and that even the group of previously infected SARS-CoV-2 patients benefit from a vaccination six months after the infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Odainic</LastName><ForeName>Alexandru</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Peter Doherty Institute for Infection &amp; Immunity, University of Melbourne, Melbourne, VIC 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spitzer</LastName><ForeName>Jasper</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9696-2092</Identifier><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szlapa</LastName><ForeName>Jennifer Barbara</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Institute of Experimental Immunology, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schade</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xe4;mer</LastName><ForeName>Tim Jonas</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neuberger</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bode</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0830-870X</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinhagen</LastName><ForeName>Folkert</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmithausen</LastName><ForeName>Ricarda Maria</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0002-3736-8672</Identifier><AffiliationInfo><Affiliation>Institute for Hygiene and Public Health, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilbring</LastName><ForeName>Gero</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute for Hygiene and Public Health, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sib</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Hygiene and Public Health, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mutters</LastName><ForeName>Nico Tom</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>Institute for Hygiene and Public Health, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabenschlag</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Medical Corps of the German Armed Forces, German Armed Forces Central Hospital, 56072 Koblenz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kettel</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Corps of the German Armed Forces, German Armed Forces Central Hospital, 56072 Koblenz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woznitza</LastName><ForeName>Maike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Corps of the German Armed Forces, German Armed Forces Central Hospital, 56072 Koblenz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Bremen</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peers</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clare Park Hospital, Farnham GU10 5XX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medinger</LastName><ForeName>Gez</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Paramedic Science, School of Health and Social Work, University of Hertfordshire, Hatfield AL10 9AB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kudaliyanage</LastName><ForeName>Anushka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreutzenbeck</LastName><ForeName>Maike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strube</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Quanterix Corporation, Billerica, MA 01821, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattoon</LastName><ForeName>Dawn</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Quanterix Corporation, Billerica, MA 01821, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ball</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-5320-9364</Identifier><AffiliationInfo><Affiliation>Quanterix Corporation, Billerica, MA 01821, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scory</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Meso Scale Diagnostics, Rockville, MD 20850, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGuire</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Meso Scale Diagnostics, Rockville, MD 20850, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Putensen</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdullah</LastName><ForeName>Zeinab</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Experimental Immunology, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latz</LastName><ForeName>Catharina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8003-4547</Identifier><AffiliationInfo><Affiliation>Dardenne Eye Hospital, 53177 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Susanne Viktoria</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>01KI20343</GrantID><Agency>Federal Ministry of Education and Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody response</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">lymphocytes</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>Joseph M. Johnson, Dawn Mattoon and Andrew J. Ball work at Quanterix Corporation. Stefan Scory and Richard McGuire work at Meso Scale Diagnostics LLC. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>27</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36293090</ArticleId><ArticleId IdType="pmc">PMC9602709</ArticleId><ArticleId IdType="doi">10.3390/ijms232012231</ArticleId><ArticleId IdType="pii">ijms232012231</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu Y.-C., Kuo R.-L., Shih S.-R. COVID-19: The first documented coronavirus pandemic in history. Biomed. J. 2020;43:328&#x2013;333. doi: 10.1016/j.bj.2020.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2020.04.007</ArticleId><ArticleId IdType="pmc">PMC7199674</ArticleId><ArticleId IdType="pubmed">32387617</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Tracking SARS-CoV-2 Variants. 2022.  [(accessed on 29 July 2022)].  Available online:  https://www.who.int/activities/tracking-SARS-CoV-2-variants.</Citation></Reference><Reference><Citation>World Health Organization  (COVID-19) Homepage. WHO Coronavirus (COVID-19) Dashboard. 2022.  [(accessed on 29 July 2022)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Diamond M.S., Kanneganti T.-D. Innate immunity: The first line of defense against SARS-CoV-2. Nat. Immunol. 2022;23:165&#x2013;176. doi: 10.1038/s41590-021-01091-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01091-0</ArticleId><ArticleId IdType="pmc">PMC8935980</ArticleId><ArticleId IdType="pubmed">35105981</ArticleId></ArticleIdList></Reference><Reference><Citation>Hojyo S., Uchida M., Tanaka K., Hasebe R., Tanaka Y., Murakami M., Hirano T. How COVID-19 induces cytokine storm with high mortality. Inflamm. Regen. 2020;40:1&#x2013;7. doi: 10.1186/s41232-020-00146-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-020-00146-3</ArticleId><ArticleId IdType="pmc">PMC7527296</ArticleId><ArticleId IdType="pubmed">33014208</ArticleId></ArticleIdList></Reference><Reference><Citation>van Paassen J., Vos J.S., Hoekstra E.M., Neumann K.M.I., Boot P.C., Arbous S.M. Corticosteroid use in COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Crit. Care. 2020;24:1&#x2013;22. doi: 10.1186/s13054-020-03400-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03400-9</ArticleId><ArticleId IdType="pmc">PMC7735177</ArticleId><ArticleId IdType="pubmed">33317589</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B., Wang S., Zhou M., Huang Y., Fu R., Guo C., Chen J., Zhao J., Gaskin F., Fu S.M., et al. The ratio of circulating follicular T helper cell to follicular T regulatory cell is correlated with disease activity in systemic lupus erythematosus. Clin. Immunol. 2017;183:46&#x2013;53. doi: 10.1016/j.clim.2017.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2017.07.004</ArticleId><ArticleId IdType="pmc">PMC5673570</ArticleId><ArticleId IdType="pubmed">28709914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantini F., Niccoli L., Matarrese D., Nicastri E., Stobbione P., Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J. Infect. 2020;81:318&#x2013;356. doi: 10.1016/j.jinf.2020.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.04.017</ArticleId><ArticleId IdType="pmc">PMC7177073</ArticleId><ArticleId IdType="pubmed">32333918</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444&#x2013;1448. doi: 10.1126/science.abb2762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2762</ArticleId><ArticleId IdType="pmc">PMC7164635</ArticleId><ArticleId IdType="pubmed">32132184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q.X., Liu B.Z., Deng H.J., Wu G.C., Deng K., Chen Y.K., Liao P., Qiu J.F., Lin Y., Cai X.F., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 2020;26:845&#x2013;848. doi: 10.1038/s41591-020-0897-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0897-1</ArticleId><ArticleId IdType="pubmed">32350462</ArticleId></ArticleIdList></Reference><Reference><Citation>Juno J.A., Tan H.X., Lee W.S., Reynaldi A., Kelly H.G., Wragg K., Esterbauer R., Kent H.E., Batten C.J., Mordant F.L., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 2020;26:1428&#x2013;1434. doi: 10.1038/s41591-020-0995-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0995-0</ArticleId><ArticleId IdType="pubmed">32661393</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., C&#xe1;rdenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against COVID-19. N. Engl. J. Med. 2021;384:2187&#x2013;2201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99&#x2013;111. doi: 10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung I.F.N., Poland G.A. Single-dose Oxford&#x2013;AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet. 2021;397:854&#x2013;855. doi: 10.1016/S0140-6736(21)00528-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00528-6</ArticleId><ArticleId IdType="pmc">PMC8086170</ArticleId><ArticleId IdType="pubmed">33676614</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  The Janssen Ad26.COV2.S COVID-19 Vaccine: What You Need to Know. 2022.  [(accessed on 29 July 2022)].  Available online:  https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-what-you-need-to-know.</Citation></Reference><Reference><Citation>World Health Organization  The Moderna COVID-19 (mRNA-1273) Vaccine: What you Need to Know. 2022.  [(accessed on 29 July 2022)].  Available online:  https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know.</Citation></Reference><Reference><Citation>World Health Organization  Interim Recommendations for Use of the Pfizer&#x2013;BioNTech COVID-19 Vaccine, BNT162b2, under Emergency Use Listing. 2022.  [(accessed on 29 July 2022)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1.</Citation></Reference><Reference><Citation>Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., et al. An mRNA vaccine against SARS-CoV-2&#x2014;Preliminary report. N. Engl. J. Med. 2020;383:1920&#x2013;1931. doi: 10.1056/NEJMoa2022483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022483</ArticleId><ArticleId IdType="pmc">PMC7377258</ArticleId><ArticleId IdType="pubmed">32663912</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020;283:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz F.X., Stiasny K. Distinguishing features of current COVID-19 vaccines: Knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021;6:1&#x2013;13. doi: 10.1038/s41541-021-00369-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00369-6</ArticleId><ArticleId IdType="pmc">PMC8368295</ArticleId><ArticleId IdType="pubmed">34400651</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner J.S., O&#x2019;Halloran J.A., Kalaidina E., Kim W., Schmitz A.J., Zhou J.Q., Lei T., Thapa M., Chen R.E., Case J.B., et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021;596:109&#x2013;113. doi: 10.1038/s41586-021-03738-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03738-2</ArticleId><ArticleId IdType="pmc">PMC8935394</ArticleId><ArticleId IdType="pubmed">34182569</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T., Ellingson M.K., Wong P., Israelow B., Lucas C., Klein J., Silva J., Mao T., Oh J.E., Tokuyama M., et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315&#x2013;320. doi: 10.1038/s41586-020-2700-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2700-3</ArticleId><ArticleId IdType="pmc">PMC7725931</ArticleId><ArticleId IdType="pubmed">32846427</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan D., Johnson J.M., Fernandes S.C., Suib H., Hwang S., Wuelfing D., Mendes M., Holdridge M., Burke E.M., Beauregard K., et al. N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection. Nat. Commun. 2021;12:1&#x2013;8. doi: 10.1038/s41467-021-22072-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22072-9</ArticleId><ArticleId IdType="pmc">PMC7997897</ArticleId><ArticleId IdType="pubmed">33771993</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., Lam E.C., Astudillo M.G., Yang D., Miller T.E., Feldman J., Hauser B.M., Caradonna T.M., Clayton K.L., Nitido A.D., et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184:476&#x2013;488. doi: 10.1016/j.cell.2020.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.015</ArticleId><ArticleId IdType="pmc">PMC7837114</ArticleId><ArticleId IdType="pubmed">33412089</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding T., Su R., Wu R., Xue H., Wang Y., Su R., Gao C., Li X., Wang C. Frontiers of autoantibodies in autoimmune disorders: Crosstalk between Tfh/Tfr and regulatory B cells. Front. Immunol. 2021;12:641013. doi: 10.3389/fimmu.2021.641013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.641013</ArticleId><ArticleId IdType="pmc">PMC8033031</ArticleId><ArticleId IdType="pubmed">33841422</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabrish S., Desai M., Saxena V., Kelkar M., Madkaikar M. IFN-g: IL-10 ratio: A putative predictive biomarker to discriminate HLH from severe viral infections. J. Clin. Immunol. 2019;39:135&#x2013;137. doi: 10.1007/s10875-019-00601-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-019-00601-y</ArticleId><ArticleId IdType="pubmed">30783923</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurath M.F., &#xdc;berla K., Ng S.C. Gut as viral reservoir: Lessons from gut viromes, HIV and COVID-19. Gut. 2021;70:1605. doi: 10.1136/gutjnl-2021-324622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324622</ArticleId><ArticleId IdType="pubmed">33903146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Le Gars M., Shukarev G., Heerwegh D., Truyers C., de Marit Groot A., Stoop J., Tete S., Van Damme W., Leroux-Roels I., et al. Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: Interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. MedRxiv. 2020 doi: 10.1101/2020.09.23.20199604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.23.20199604</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal V., Nepal G., Dijamco P., Ishak A., Dagar M., Sarfraz Z., Shama N., Sarfraz A., Lnu K., Mitra S., et al. Cerebral Venous Sinus Thrombosis Following COVID-19 Vaccination: A Systematic Review. J. Prim. Care Community Health. 2022;13:21501319221074450. doi: 10.1177/21501319221074450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/21501319221074450</ArticleId><ArticleId IdType="pmc">PMC8841914</ArticleId><ArticleId IdType="pubmed">35142234</ArticleId></ArticleIdList></Reference><Reference><Citation>Impfkommission S. Beschluss der STIKO zur 20. Aktualisierung der COVID-19-Impfempfehlung. Epidemiol. Bull. 2022;21:3&#x2013;19.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  [(accessed on 29 July 2022)];2022  Available online:  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#infection.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Science Brief: SARS-CoV-2 Infection-Induced and Vaccine-Induced Immunity.  [(accessed on 29 July 2022)];2021  Available online:  https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-immunity.html.</Citation><ArticleIdList><ArticleId IdType="pubmed">34748301</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration  Summary of FDA &amp; EMA Global Regulators Meeting on Data Requirements Supporting First-in-Human Clinical Trials with SARS-CoV-2 Vaccines.  [(accessed on 29 July 2022)];2020  Available online:  https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/summary-fda-ema-global-regulators-meeting-data-requirements-supporting-first-human-clinical-trials.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration  FDA Takes Key Action in Fight against COVID-19 by Issuing Emergency Use Authorization for First COVID-19 Vaccine.  [(accessed on 29 July 2022)];2020  Available online:  https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19.</Citation></Reference><Reference><Citation>Bao Y., Ling Y., Chen Y.-Y., Tian D., Zhao G.-P., Zhang X.-H., Hang H., Li Y., Su B., Lu H.-Z., et al. Dynamic anti-spike protein antibody profiles in COVID-19 patients. Int. J. Infect. Dis. 2021;103:540&#x2013;548. doi: 10.1016/j.ijid.2020.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.12.014</ArticleId><ArticleId IdType="pmc">PMC7836795</ArticleId><ArticleId IdType="pubmed">33310028</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2020;384:403&#x2013;416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Favresse J., Gillot C., Di Chiaro L., Eucher C., Elsen M., Van Eeckhoudt S., David C., Morimont L., Dogn&#xe9; J.-M., Douxfils J. Neutralizing antibodies in COVID-19 patients and vaccine recipients after two doses of BNT162b2. Viruses. 2021;13:1364. doi: 10.3390/v13071364.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13071364</ArticleId><ArticleId IdType="pmc">PMC8309994</ArticleId><ArticleId IdType="pubmed">34372570</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson M.G., Burgess J.L., Naleway A.L., Tyner H., Yoon S.K., Meece J., Olsho L.E.W., Caban-Martinez A.J., Fowlkes A.L., Lutrick K., et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N. Engl. J. Med. 2021;385:320&#x2013;329. doi: 10.1056/NEJMoa2107058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107058</ArticleId><ArticleId IdType="pmc">PMC8262622</ArticleId><ArticleId IdType="pubmed">34192428</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R., Zhu L., Xue L., Liu L., Yan X., Wang J., Zhang B., Xu T., Ji F., Zhao Y., et al. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. PLoS Negl. Trop. Dis. 2020;14:e0008280. doi: 10.1371/journal.pntd.0008280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0008280</ArticleId><ArticleId IdType="pmc">PMC7239492</ArticleId><ArticleId IdType="pubmed">32384078</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., Wu D., Chen H., Yan W., Yang D., Chen G., Ma K., Xu D., Yu H., Wang H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1091</ArticleId><ArticleId IdType="pmc">PMC7190011</ArticleId><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>Brochot E., Demey B., Touz&#xe9; A., Belouzard S., Dubuisson J., Schmit J.L., Duverlie G., Francois C., Castelain S., Helle F. Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals. Front. Microbiol. 2020;11:2468. doi: 10.3389/fmicb.2020.584251.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.584251</ArticleId><ArticleId IdType="pmc">PMC7604306</ArticleId><ArticleId IdType="pubmed">33193227</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Matthews P.C., Stoesser N., Maddox T., Lorenzi L., Studley R., Bell J.I., Newton J.N., Farrar J., Diamond I., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nat. Commun. 2021;12:1&#x2013;12. doi: 10.1038/s41467-021-26479-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26479-2</ArticleId><ArticleId IdType="pmc">PMC8556331</ArticleId><ArticleId IdType="pubmed">34716320</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett K.S., Gagne M., Wagner D.A., O&#x2019;Connell S., Narpala S.R., Flebbe D.R., Andrew S.F., Davis R.L., Flynn B., Johnston T.S., et al. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine&#x2013;boosted nonhuman primates. Science. 2021;374:1343&#x2013;1353. doi: 10.1126/science.abl8912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl8912</ArticleId><ArticleId IdType="pubmed">34672695</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman J., Thakur N., Peacock T.P., Bialy D., Elrefaey A.M., Bogaardt C., Horton D.L., Ho S., Kankeyan T., Carr C., et al. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Nat. Microbiol. 2022;7:1180&#x2013;1188. doi: 10.1038/s41564-022-01163-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01163-3</ArticleId><ArticleId IdType="pmc">PMC9352594</ArticleId><ArticleId IdType="pubmed">35836002</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Shitany N.A., Harakeh S., Badr-Eldin S.M., Bagher A.M., Eid B., Almukadi H., Alghamdi B.S., Alahmadi A.A., Hassan N.A., Sindi N., et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. Int. J. Gen. Med. 2021;14:1389. doi: 10.2147/IJGM.S310497.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S310497</ArticleId><ArticleId IdType="pmc">PMC8068468</ArticleId><ArticleId IdType="pubmed">33907443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling R.R., Ramanathan K., Tan F.L., Tai B.C., Somani J., Fisher D., MacLaren G. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: A systematic review and meta-analysis. Lancet Respir. Med. 2022;10:679&#x2013;688. doi: 10.1016/S2213-2600(22)00059-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00059-5</ArticleId><ArticleId IdType="pmc">PMC9000914</ArticleId><ArticleId IdType="pubmed">35421376</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins H., Andrews N., Stowe J., Amirthalingam G., Ramsay M., Bahra G., Hackett A., Breen K.A., Desborough M., Khan D., et al. Risk of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination prior to the recognition of vaccine-induced thrombocytopenia and thrombosis: A self-controlled case series study in England. Res. Pract. Thromb. Haemost. 2022;6:e12698. doi: 10.1002/rth2.12698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12698</ArticleId><ArticleId IdType="pmc">PMC9020167</ArticleId><ArticleId IdType="pubmed">35475292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindoli S., Giollo A., Galozzi P., Doria A., Sfriso P. Hyperinflammation after anti-SARS-CoV-2 mRNA/DNA vaccines successfully treated with anakinra: Case series and literature review. Exp. Biol. Med. 2022;247:338&#x2013;344. doi: 10.1177/15353702211070290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/15353702211070290</ArticleId><ArticleId IdType="pmc">PMC8899337</ArticleId><ArticleId IdType="pubmed">35068221</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam P.S., Scott M.K.D., Hagan T., Li C., Feng Y., Wimmers F., Grigoryan L., Trisal M., Edara V.V., Lai L., et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021;596:410&#x2013;416. doi: 10.1038/s41586-021-03791-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03791-x</ArticleId><ArticleId IdType="pmc">PMC8761119</ArticleId><ArticleId IdType="pubmed">34252919</ArticleId></ArticleIdList></Reference><Reference><Citation>Alijotas-Reig J., Imenez V.G., Velthuis P.J., Niessen F.B., Decates T.S. Inflammatory immune-mediated adverse reactions induced by COVID-19 vaccines in previously injected patients with soft tissue fillers: A case-series of 20 patients. J. Cosmet. Dermatol. 2022;21:3181&#x2013;3187. doi: 10.1111/jocd.15117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocd.15117</ArticleId><ArticleId IdType="pmc">PMC9347616</ArticleId><ArticleId IdType="pubmed">35621234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbinati N., Esposito C., Cipolla G., Calligaro A., Monticelli D., Martina V., Golubovic M., Binic I., Sigova J., Gallo A.L., et al. Chemical and mechanical characterization of hyaluronic acid hydrogel cross-linked with polyethylen glycol and its use in dermatology. Dermatol. Ther. 2020;33:e13747. doi: 10.1111/dth.13747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.13747</ArticleId><ArticleId IdType="pubmed">32475040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellaturay P., Nasser S., Islam S., Gurugama P., Ewan P.W. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin. Exp. Allergy. 2021;51:861. doi: 10.1111/cea.13874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.13874</ArticleId><ArticleId IdType="pmc">PMC8251011</ArticleId><ArticleId IdType="pubmed">33825239</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellaturay P., Gurugama P., Harper V., Dymond T., Ewan P., Nasser S. The Polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients. Clin. Exp. Allergy. 2022;52:12&#x2013;17. doi: 10.1111/cea.14064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.14064</ArticleId><ArticleId IdType="pubmed">34822190</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox F., Khalib K., Conlon N. PEG that reaction: A case series of allergy to polyethylene glycol. J. Clin. Pharmacol. 2021;61:832&#x2013;835. doi: 10.1002/jcph.1824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.1824</ArticleId><ArticleId IdType="pmc">PMC8014770</ArticleId><ArticleId IdType="pubmed">33543766</ArticleId></ArticleIdList></Reference><Reference><Citation>Wylon K., D&#xf6;lle S., Worm M. Polyethylene glycol as a cause of anaphylaxis. Allergy Asthma Clin. Immunol. 2016;12:1&#x2013;3. doi: 10.1186/s13223-016-0172-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13223-016-0172-7</ArticleId><ArticleId IdType="pmc">PMC5155397</ArticleId><ArticleId IdType="pubmed">27999603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortz C.G., Kjaer H.F., Rasmussen T.H., Rasmussen H.M., Garvey L.H., Bindslev-Jensen C. Allergy to polyethylene glycol and polysorbates in a patient cohort: Diagnostic work-up and decision points for vaccination during the COVID-19 pandemic. Clin. Transl. Allergy. 2022;12:e12111. doi: 10.1002/clt2.12111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clt2.12111</ArticleId><ArticleId IdType="pmc">PMC8742452</ArticleId><ArticleId IdType="pubmed">35028130</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster J., Nandi D., Kulkarni A. mRNA-Carrying Lipid Nanoparticles that Induce Lysosomal Rupture Activate NLRP3 Inflammasome and Reduce mRNA Transfection Efficiency. Biomater. Sci. 2022;10:5566&#x2013;5582. doi: 10.1039/D2BM00883A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2BM00883A</ArticleId><ArticleId IdType="pubmed">35971974</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L., Zhang H., Dauphars D.J., He Y.-W. A potential role of interleukin 10 in COVID-19 pathogenesis. Trends Immunol. 2021;42:3&#x2013;5. doi: 10.1016/j.it.2020.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2020.10.012</ArticleId><ArticleId IdType="pmc">PMC7605819</ArticleId><ArticleId IdType="pubmed">33214057</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas J.M., Avia M., Mart&#xed;n V., Sevilla N. IL-10: A multifunctional cytokine in viral infections. J. Immunol. Res. 2017;2017:6104054. doi: 10.1155/2017/6104054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/6104054</ArticleId><ArticleId IdType="pmc">PMC5337865</ArticleId><ArticleId IdType="pubmed">28316998</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagn M., Jahrsd&#xf6;rfer B. Why do human B cells secrete granzyme B? Insights into a novel B-cell differentiation pathway. Oncoimmunology. 2012;1:1368&#x2013;1375. doi: 10.4161/onci.22354.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/onci.22354</ArticleId><ArticleId IdType="pmc">PMC3518509</ArticleId><ArticleId IdType="pubmed">23243600</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkaya M., Kwak K., Pierce S.K. B cell memory: Building two walls of protection against pathogens. Nat. Rev. Immunol. 2020;20:229&#x2013;238. doi: 10.1038/s41577-019-0244-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0244-2</ArticleId><ArticleId IdType="pmc">PMC7223087</ArticleId><ArticleId IdType="pubmed">31836872</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley G.E., Edwards E.S., Aui P.M., Varese N., Stojanovic S., McMahon J., Peleg A.Y., Boo I., Drummer H.E., Hogarth P.M., et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci. Immunol. 2020;5:eabf8891. doi: 10.1126/sciimmunol.abf8891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf8891</ArticleId><ArticleId IdType="pmc">PMC7877496</ArticleId><ArticleId IdType="pubmed">33443036</ArticleId></ArticleIdList></Reference><Reference><Citation>Force A.D.T., Ranieri V.M., Rubenfeld G.D., Thompson B., Ferguson N., Caldwell E., Fan E., Camporota L., Slutsky A.S. Acute respiratory distress syndrome. JAMA. 2012;307:2526&#x2013;2533.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>R. C. Team  . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2013.  [(accessed on 1 April 2022)].  Available online:  http://www.R-project.org/</Citation></Reference><Reference><Citation>Kassambara A. rstatix: Pipe-Friendly Framework for Basic Statistical Tests, R package version 0.7.0. 2021.  [(accessed on 25 May 2022)].  Available online:  http://www.R-project.org/</Citation></Reference><Reference><Citation>Sjoberg D.D., Whiting K., Curry M., Lavery J.A., Larmarange J. Reproducible Summary Tables with the gtsummary Package. R J. 2021;13:570&#x2013;594. doi: 10.32614/RJ-2021-053.</Citation><ArticleIdList><ArticleId IdType="doi">10.32614/RJ-2021-053</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H. ggplot2. Springer; Berlin/Heidelberg, Germany: 2016. Data analysis; pp. 189&#x2013;201.</Citation></Reference><Reference><Citation>Kassambara A. ggpubr: &#x2018;ggplot2&#x2019; based Publication Ready Plots. Github; San Francisco, CA, USA: 2020.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>